Atai Life Sciences N.V. (NASDAQ: ATAI) stock fell -2.56% on Friday to $1.90 against a previous-day closing price of $1.95. With 1.22 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.39 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.9600 whereas the lowest price it dropped to was $1.8800. The 52-week range on ATAI shows that it touched its highest point at $6.32 and its lowest point at $1.45 during that stretch. It currently has a 1-year price target of $13.58.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATAI was up-trending over the past week, with a rise of 3.83%, but this was down by -35.59% over a month. Three-month performance dropped to -27.76% while six-month performance fell -52.85%. The stock lost -65.95% in the past year, while it has lost -28.57% so far this year. A look at the trailing 12-month EPS for ATAI yields -1.29 with Next year EPS estimates of -1.02. For the next quarter, that number is -0.23. This implies an EPS growth rate of -9.00% for this year and -12.10% for next year.
Float and Shares Shorts:
At present, 156.61 million ATAI shares are outstanding with a float of 150.49 million shares on hand for trading. On Oct 13, 2022, short shares totaled 6.28 million, which was 3.79% higher than short shares on Sep 14, 2022. In addition to Mr. Christian Angermayer as the firm’s Founder & Chairman of the Supervisory Board, Mr. Florian Brand serves as its Co-founder & CEO.
Through their ownership of 35.58% of ATAI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.71% of ATAI, in contrast to 7.02% held by mutual funds. Shares owned by individuals account for 19.95%. As the largest shareholder in ATAI with 3.70% of the stake, ARK Investment Management LLC holds 6,138,914 shares worth 6,138,914. A second-largest stockholder of ATAI, Alpha Wave Global LP, holds 2,134,625 shares, controlling over 1.29% of the firm’s shares. Morgan Stanley Investment Managem is the third largest shareholder in ATAI, holding 1,480,735 shares or 0.89% stake. With a 3.41% stake in ATAI, the ARK Genomic Revolution ETF is the largest stakeholder. A total of 5,648,252 shares are owned by the mutual fund manager. The iShares Biotechnology ETF, which owns about 0.62% of ATAI stock, is the second-largest Mutual Fund holder. It holds 1,021,424 shares valued at 2.72 million. Morgan Stanley Instl. Fund Tr. – holds 0.36% of the stake in ATAI, owning 601,270 shares worth 1.6 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATAI since 14 analysts follow the stock currently. There are 13 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATAI analysts setting a high price target of $21.00 and a low target of $5.10, the average target price over the next 12 months is $12.66. Based on these targets, ATAI could surge 1005.26% to reach the target high and rise by 168.42% to reach the target low. Reaching the average price target will result in a growth of 566.32% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ATAI will report FY 2022 earnings on 03/27/2024. Analysts have provided yearly estimates in a range of -$0.70 being high and -$1.06 being low. For ATAI, this leads to a yearly average estimate of -$0.91. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Atai Life Sciences N.V. surprised analysts by $0.02 when it reported -$0.22 EPS against a consensus estimate of -$0.24. The surprise factor in the prior quarter was -$0.00. Based on analyst estimates, the high estimate for the next quarter is -$0.13 and the low estimate is -$0.28. The average estimate for the next quarter is thus -$0.23.